 |
|
Fluphenazine Decanoate, Oral Fluphenazine, and Placebo in Treatment of Remitted SchizophrenicsII. Rating Scale Data
Arthur Rifkin, MD;
Frederic Quitkin, MD;
Donald F. Klein, MD
Arch Gen Psychiatry. 1977;34(10):1215-1219.
Abstract
• This study of patients with remitted chronic schizophrenia in an aftercare clinic was designed to test whether such patients require maintenance antipsychotic medication. A previous report showed that the group receiving active medication, fluphenazine decanoate and oral fluphenazine, had far fewer relapses; but the former group had a high incidence of akinesia. This present report presents rating scale data substantiating these two findings: (1) patients terminated on clinical grounds because of a schizophrenic relapse showed rating scale changes consistent with that diagnosis; and (2) the patients removed due to severe akinesia showed a worsening on items selected a priori to measure akinesia, and when compared to survivors on the same items, showed significant differences— thus confirming our clinical judgments.
Author Affiliations
From the Hillside Division, Long Island Jewish-Hillside Medical Center, Glen Oaks, NY. The authors are now at the New York State Psychiatric Institute, and the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York.
Footnotes
Accepted for publication Oct 4, 1976.
Reprint requests to New York State Psychiatric Institute, 722 West 168th St, New York, NY 10032 (Dr Rifkin).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia
Keith et al.
Psychiatr. Serv. 2004;55:997-1005.
ABSTRACT
| FULL TEXT
|
